News headlines about Codexis (NASDAQ:CDXS) have trended somewhat positive on Friday, Accern reports. The research firm rates the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Codexis earned a media sentiment score of 0.13 on Accern’s scale. Accern also assigned media headlines about the biotechnology company an impact score of 46.7925869716636 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news stories that may have effected Accern’s scoring:

Codexis opened at $13.25 on Friday, according to Marketbeat Ratings. The company has a market cap of $705.43 million, a P/E ratio of -26.50 and a beta of -1.71. Codexis has a one year low of $13.40 and a one year high of $14.05. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.61 and a current ratio of 1.67.

Codexis (NASDAQ:CDXS) last released its quarterly earnings results on Thursday, May 10th. The biotechnology company reported ($0.10) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.08) by ($0.02). The business had revenue of $14.04 million for the quarter, compared to the consensus estimate of $13.50 million. Codexis had a negative return on equity of 87.65% and a negative net margin of 36.06%. analysts forecast that Codexis will post -0.25 earnings per share for the current fiscal year.

A number of research firms recently commented on CDXS. Zacks Investment Research lowered Codexis from a “hold” rating to a “sell” rating in a research report on Friday, February 9th. ValuEngine upgraded Codexis from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. BidaskClub upgraded Codexis from a “buy” rating to a “strong-buy” rating in a research report on Saturday, March 3rd. HC Wainwright set a $12.00 price target on Codexis and gave the stock a “buy” rating in a research report on Monday, March 12th. Finally, Stephens began coverage on Codexis in a research report on Wednesday. They set an “overweight” rating and a $16.00 price target on the stock. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has issued a strong buy rating to the company’s stock. Codexis currently has an average rating of “Buy” and a consensus price target of $13.25.

In other Codexis news, SVP James Lalonde sold 10,000 shares of the stock in a transaction on Monday, May 14th. The stock was sold at an average price of $13.09, for a total value of $130,900.00. Following the transaction, the senior vice president now directly owns 220,066 shares in the company, valued at approximately $2,880,663.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Thomas R. Baruch sold 25,000 shares of the stock in a transaction on Thursday, March 29th. The shares were sold at an average price of $11.05, for a total value of $276,250.00. Following the completion of the transaction, the director now owns 184,670 shares in the company, valued at $2,040,603.50. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 137,337 shares of company stock worth $1,602,603. 9.80% of the stock is owned by corporate insiders.

Codexis Company Profile

Codexis, Inc discovers, develops, and sells protein catalysts. It also offers intermediate chemicals products that are used for further chemical processing; and Codex biocatalyst panels and kits that enable customers to perform chemistry screening. The company also provides protein catalyst screening and protein engineering services.

Insider Buying and Selling by Quarter for Codexis (NASDAQ:CDXS)

Receive News & Ratings for Codexis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Codexis and related companies with MarketBeat.com's FREE daily email newsletter.